Of the remaining four patients evaluable for DLT in dose level 3, two patients had first cycle DLT (grade 2 ALT elevation that did not resolve within 14 days; grade 4 neutropenia > 7 days). The gene discussed is GPT; the disease is Decreased total neutrophil count.